☆ 4.8 Article

COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants

NATURE COMMUNICATIONS (2021)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Immunology

Magnitude and Kinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Responses and Their Relationship to Disease Severity

Kara L. Lynch et al.

Summary: Understanding the kinetics and magnitude of the host antibody response to SARS-CoV-2 is essential for understanding the pathogenesis of COVID-19 and identifying potential therapeutic targets. Research showed that IgM and IgG responses were significantly higher in patients with severe disease compared to those with mild disease, which may have implications for seroprevalence studies, therapeutics, and vaccine development strategies.

CLINICAL INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Spike mutation D614G alters SARS-CoV-2 fitness

Jessica A. Plante et al.

Summary: The D614G substitution in the SARS-CoV-2 spike protein enhances viral replication and infectivity in human lung epithelial cells, primary airway tissues, and hamsters. This variant may increase transmission in the upper respiratory tract and doesn't seem to significantly reduce vaccine efficacy. Further research on therapeutic antibodies targeting the circulating G614 virus is recommended.

NATURE (2021)

添加到收藏夹

Letter Infectious Diseases

Prior SARS-CoV-2 infection is associated with protection against symptomatic reinfection

Aidan T. Hanrath et al.

JOURNAL OF INFECTION (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera

Daming Zhou et al.

Summary: The race to develop vaccines against SARS-CoV-2 variants, such as B.1.1.7, B.1.351, and P.1, is ongoing as these variants have mutations in the spike protein, potentially leading to immune escape. A structure-function analysis of B.1.351 revealed tighter ACE2 binding and widespread evasion from monoclonal antibody neutralization, particularly driven by the E484K mutation.

CELL (2021)

添加到收藏夹

Article Microbiology

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines

Xiaoying Shen et al.

Summary: Current COVID-19 vaccines target the ancestral SARS-CoV-2 spike, but the emerging B.1.1.7 variant with multiple spike mutations may impact some antibody therapies while posing no major concerns for vaccine efficacy or increased risk of reinfection.

CELL HOST & MICROBE (2021)

添加到收藏夹

Letter Immunology

Impressive Boosting of Anti-S1/S2 Immunoglobulin G Production in Coronavirus Disease 2019 (COVID-19)-experienced Patients After the First Shot of the BNT162b2 Messenger RNA COVID-19 Vaccine

Amedeo F. Capetti et al.

CLINICAL INFECTIOUS DISEASES (2021)

添加到收藏夹

Letter Medicine, General & Internal

Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2

Saman Saadat et al.

Summary: This study compared the titers of binding and neutralizing antibodies in healthcare workers previously infected with SARS-CoV-2 after receiving a single dose of mRNA coronavirus vaccine.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Letter Medicine, General & Internal

Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients

Sharon Amit et al.

LANCET (2021)

添加到收藏夹

Article Multidisciplinary Sciences

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Zijun Wang et al.

Summary: Volunteers who received the Moderna or Pfizer-BioNTech vaccine showed high levels of antibodies and memory B cell responses against SARS-CoV-2, with activity similar to individuals who had recovered from natural infection. However, their efficacy against specific SARS-CoV-2 variants was reduced, indicating a potential need for periodic updates to mRNA vaccines to maintain clinical efficacy.

NATURE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

Constantinos Kurt Wibmer et al.

Summary: The SARS-CoV-2 virus in the B.1.351 variant discovered in South Africa can evade neutralization by most antibodies when expressed, but does not affect binding by convalescent plasma. This suggests the potential for reinfection with antigenically distinct variants and predicts reduced efficacy of spike-based vaccines.

NATURE MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Noa Dagan et al.

Summary: A study conducted in Israel on nearly 600,000 individuals showed that the BNT162b2 mRNA vaccine was effective in reducing the risk of infection, hospitalization, and severe Covid-19. The effectiveness in preventing death was 72% during the period from day 14 through day 20 after the first dose, and hospitalization was reduced by 87% for the period 7 or more days after the second dose, similar to results from a randomized trial.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Letter Medicine, General & Internal

Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine

Florian Krammer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Letter Medicine, General & Internal

Neutralizing Activity of BNT162b2-Elicited Serum

Yang Liu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

A multiplex chemiluminescent immunoassay for serological profiling of COVID-19-positive symptomatic and asymptomatic patients

Allison N. Grossberg et al.

Summary: This study presents results from a multiplex serology test for assessing COVID-19 antibody responses, showing distinct dynamics of IgG, IgM, and IgA responses in patients with different disease severity. It suggests that antibody responses to SARS-CoV-2 may serve as important biomarkers for assessing the risk of viral transmission.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Medicine, General & Internal

SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)

Victoria Jane Hall et al.

Summary: This study investigated whether antibodies against SARS-CoV-2 were associated with a decreased risk of symptomatic and asymptomatic reinfection. It found that individuals with a previous history of SARS-CoV-2 infection had an 84% lower risk of reinfection, with a median protective effect lasting for 7 months following primary infection.

LANCET (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma

Sandile Cele et al.

Summary: The study compared the neutralization of non-VOC and 501Y.V2 VOC variants using plasma from COVID-19 patients in South Africa. It found that plasma from individuals infected during the first wave effectively neutralized the first-wave virus variant, while plasma from those infected in the second wave effectively neutralized the 501Y.V2 variant.

NATURE (2021)

添加到收藏夹

Article Microbiology

A Generic, Scalable, and Rapid Time-Resolved Forster Resonance Energy Transfer-Based Assay for Antigen Detection - SARS-CoV-2 as a Proof of Concept

Juuso Rusanen et al.

Summary: The study presented a fast and simple assay principle for antigen detection, which demonstrated high sensitivity and specificity in detecting SARS-CoV-2 antigens in nasopharyngeal swabs. The method is based on time-resolved Forster resonance energy transfer (TR-FRET) for detecting SARS-CoV-2 nucleocapsid protein (NP) and spike protein (SP).

MBIO (2021)

添加到收藏夹

Article Virology

Kinetics of Neutralizing Antibodies of COVID-19 Patients Tested Using Clinical D614G, B.1.1.7, and B 1.351 Isolates in Microneutralization Assays

Jenni Virtanen et al.

Summary: Newly emerged SARS-CoV-2 variants of concern show resistance to neutralization by antibodies elicited by the wild-type virus, with VoC2 having increased potential to reinfect previously SARS-CoV-infected individuals. Neutralizing antibodies in recovered patients show varied levels of inhibition against different variants, with some sera failing to neutralize VoC2.

VIRUSES-BASEL (2021)

添加到收藏夹

Article Medicine, General & Internal

Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization

Gabriel Chodick et al.

Summary: The short-term effectiveness of the first dose of the BNT162b2 vaccine against SARS-CoV-2 infection 13 to 24 days after immunization in a real-world setting was assessed, showing comparable results to the phase III randomized clinical trial.

JAMA NETWORK OPEN (2021)

添加到收藏夹

Article Immunology

A Combination of N and S Antigens With IgA and IgG Measurement Strengthens the Accuracy of SARS-CoV-2 Serodiagnostics

Pinja Jalkanen et al.

Summary: Utilizing SARS-CoV-2 nucleoprotein (N) and receptor binding domain (RBD) as antigens in enzyme immunoassays (EIA) among COVID-19 patients showed sensitivity of 77% in the acute phase and 100% in the convalescent phase. Furthermore, SARS-CoV-2 infection significantly increased humoral immune responses against other human coronaviruses.

JOURNAL OF INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Medicine, Research & Experimental

Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes

Edwards Pradenas et al.

Summary: The study found that individuals with mild or asymptomatic infections experienced an insignificant decrease in neutralizing activity, which persisted for 6 months after symptom onset or diagnosis. Hospitalized individuals exhibited higher neutralizing titers, which decreased rapidly at first but significantly slowed down after day 80, remaining higher than those with mild symptoms at 6 months. This slow decline in neutralizing activity contrasted with the constant decrease in anti-RBD, S2, or NP antibody titers over the follow-up period.

MED (2021)

添加到收藏夹

Letter Infectious Diseases

An interactive web-based dashboard to track COVID-19 in real time

Ensheng Dong et al.

LANCET INFECTIOUS DISEASES (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Alexandra C. Walls et al.

CELL (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

A serological assay to detect SARS-CoV-2 seroconversion in humans

Fatima Amanat et al.

NATURE MEDICINE (2020)

添加到收藏夹

Article Immunology

A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection

Wafaa B. Alsoussi et al.

JOURNAL OF IMMUNOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Pedro M. Folegatti et al.

LANCET (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques

Wei Deng et al.

SCIENCE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Ugur Sahin et al.

NATURE (2020)

添加到收藏夹

Article Medicine, General & Internal

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Edward E. Walsh et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

E. J. Anderson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo

Yixuan J. Hou et al.

SCIENCE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

Ania Wajnberg et al.

SCIENCE (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

A systematic review of SARS-CoV-2 vaccine candidates

Yetian Dong et al.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)

添加到收藏夹

Article Immunology

Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients

Nisreen M. A. Okba et al.

EMERGING INFECTIOUS DISEASES (2020)

添加到收藏夹

Article Biochemical Research Methods

Multiplex PCR method for MinION and Illumina sequencing of Zika and other virus genomes directly from clinical samples

Joshua Quick et al.

NATURE PROTOCOLS (2017)

添加到收藏夹

Article Biochemical Research Methods

Trimmomatic: a flexible trimmer for Illumina sequence data

Anthony M. Bolger et al.

BIOINFORMATICS (2014)

添加到收藏夹

Article Biochemical Research Methods

The Sequence Alignment/Map format and SAMtools

Heng Li et al.

BIOINFORMATICS (2009)

添加到收藏夹

Review Immunology

Vaccination in the elderly: an immunological perspective

Wilbur H. Chen et al.

TRENDS IN IMMUNOLOGY (2009)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.